Elevation of plasma oncostatin M in heart failure

Gruson, Damien;Ferracin, Benjamin;Ahn, Sylvie A.;Rousseau, Michel
(2017) Future Cardiology — Vol. 13, n° 3, p. 219-227 (2017)

Files

ElevationofplasmaoncostatinMinheartfailure.pdf
  • Open Access
  • Adobe PDF
  • 93.59 KB
Download

Details

Authors
  • Gruson, DamienUCLouvain
    Author
  • Ferracin, BenjaminUCLouvain
    Author
  • Ahn, Sylvie A.UCLouvain
    Author
  • Rousseau, MichelUCLouvain
    Author
Abstract
(en) Oncostatin M (OSM) is an inflammatory cytokine of the gp130 family. OSM could participate in adverse cardiovascular remodeling through regulation of FGF23. Materials & methods: OSM levels were determined in 80 heart failure patients with reduced left ventricular ejection fraction (HFrEF). Results: OSM levels are significantly increased in HFrEF patients compared with healthy subjects. We have also demonstrated that, in HFrEF patients, plasma OSM levels are correlated to parathyroid hormone PTH(1–84) and 1,25(OH)2D, two other biomarkers related to bone and mineral metabolism and associated to adverse cardiovascular outcomes
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Gruson, D., Ferracin, B., Ahn, S. A., & Rousseau, M. (2017). Elevation of plasma oncostatin M in heart failure. Future Cardiology, 13(3), 219-227. https://doi.org/10.2217/fca-2016-0063 (Original work published 2017)